It should be noted, that when using a univariate Cox proportional Hazards ratio model per every cancer type or adjusting by TMB ≥ 10, the results were also similar in the overall population of this study, but the clinical impact of AID-related fraction of mutations was only found in metastatic melanoma and cancer with unknown primary (Fig. 3c; Supplementary Fig. 13). This evidence concerns the gene AICDA and metastatic melanoma.